

Estrogen Receptor β Binds to and Regulates Three Distinct Classes of Target Genes*[§]

Received for publication, February 14, 2010, and in revised form, April 14, 2010. Published, JBC Papers in Press, April 19, 2010, DOI 10.1074/jbc.M110.114116

Omar I. Vivar^{†1}, Xiaoyue Zhao^{§1}, Elise F. Saunier[§], Chandi Griffin[§], Oleg S. Mayba[¶], Mary Tagliaferri[§], Isaac Cohen[§], Terence P. Speed^{¶||2}, and Dale C. Leitman^{‡2,3}

From the [†]Department of Nutritional Science and Toxicology, University of California, Berkeley, California 94720, [§]Bionovo, Inc., Emeryville, California 94608, the [¶]Department of Statistics, University of California, Berkeley, California 94720, and the ^{||}Division of Bioinformatics, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia

Estrogen receptor β (ER β) has potent antiproliferative and anti-inflammatory properties, suggesting that ER β -selective agonists might be a new class of therapeutic and chemopreventive agents. To understand how ER β regulates genes, we identified genes regulated by the unliganded and liganded forms of ER α and ER β in U2OS cells. Microarray data demonstrated that virtually no gene regulation occurred with unliganded ER α , whereas many genes were regulated by estradiol (E₂). These results demonstrated that ER α requires a ligand to regulate a single class of genes. In contrast, ER β regulated three classes of genes. Class I genes were regulated primarily by unliganded ER β . Class II genes were regulated only with E₂, whereas class III genes were regulated by both unliganded ER β and E₂. There were 453 class I genes, 258 class II genes, and 83 class III genes. To explore the mechanism whereby ER β regulates different classes of genes, chromatin immunoprecipitation-sequencing was performed to identify ER β binding sites and adjacent transcription factor motifs in regulated genes. AP1 binding sites were more enriched in class I genes, whereas ERE, NF κ B1, and SP1 sites were more enriched in class II genes. ER β bound to all three classes of genes, demonstrating that ER β binding is not responsible for differential regulation of genes by unliganded and liganded ER β . The coactivator NCOA2 was differentially recruited to several target genes. Our findings indicate that the unliganded and liganded forms of ER β regulate three classes of genes by interacting with different transcription factors and coactivators.

Estrogens are essential for the development of the reproductive system. They also exert important actions on nonreproductive tissues such as the bone (1) and cardiovascular system (2). Many biological effects of estrogens are mediated by two estrogen receptors (ERs),⁴ estrogen receptor α (ER α ; NR3A1 and ESR1) and estrogen receptor β (ER β ; NR3A2 and ESR2) (3, 4).

* This work was supported by a grant from the American Cancer Society (to D. C. L.).

[§] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental Tables 1 and 2.

¹ Both authors contributed equally to this work.

² Members of the Scientific Advisory Board of Bionovo, Inc.

³ Recipient of a gift of financial support for research from Bionovo, Inc. To whom correspondence should be addressed: University of California, Dept. of Nutritional Science and Toxicology, 44 Morgan Hall, Berkeley, CA 94720. Tel.: 510-642-0862; E-mail: dale@leitmanlab.com.

⁴ The abbreviations used are: ER, estrogen receptor; ERE, estrogen responsive element; ChIP-Seq, chromatin immunoprecipitation-sequencing; E₂, estradiol; NCOA2, nuclear receptor coactivator 2.

The binding of estrogens to ERs produces genomic effects (3, 4) that regulate gene transcription and nongenomic effects (5) that regulate ion channels and signal transduction pathways. The genomic pathway is better characterized. This pathway is initiated by the binding of the estrogen-ER complex to specific regulatory elements in target genes. The estrogen-ER complex can bind directly to DNA via an estrogen responsive element (ERE) or become tethered to a transcription factor (3, 4). Once bound to a regulatory element, the estrogen-ER complex can interact with adjacent transcription factors and recruit a variety of coregulators that result in the activation or repression of target genes by modifying chromatin structure (6–10).

Although ER α and ER β have a similar structure, they produce different biological effects (3, 4). The ER α and ER β knockout mice have different phenotypes demonstrating that the two ERs have different physiological roles (11–13). ER α is essential for the development of the reproductive tract and mammary gland because it promotes cell proliferation. In contrast, ER β appears to have an antiproliferation role because ER β knockout mice develop prostate hyperplasia and a myeloproliferative disease (12, 14). In addition, the expression of ER β in breast and colon cancer cells inhibits cancer cell proliferation and tumor formation in mouse xenograft models (15–19), which supports an antiproliferative role for ER β . ER α and ER β regulate different genes in response to E₂ and selective estrogen receptor modulators (20, 21). For example, only ~40% of the genes regulated by E₂ in U2OS cells that express ER α are also regulated in U2OS cells that express ER β (20).

It is unclear how ER α and ER β produce unique physiological effects and regulate different genes, but it could be due to differences in their binding to different regulatory elements in target genes. ER α binding sites have been identified in MCF-7 breast cancer cells by using tiling arrays (6, 22, 23) and ChIP-Seq (24). In contrast to ER α , very little is known about the binding sites for ER β in the genome. However, because of the antiproliferative properties of ER β , a greater understanding of how it regulates genes is critical to develop ER β -selective drugs that might be useful for chemoprevention of cancers. Although genome-wide analysis by tiling arrays and ChIP-Seq are powerful methods to identify ER binding sites and transcription factors that are associated with ER binding sites, it is clear from these studies that most of the binding sites detected by these methods are not functionally active (6, 22, 23). Furthermore, it is difficult to determine which ER binding site is associated with a particular regulated gene. For example, we used a ChIP-se-

Genome-wide ER β Binding Sites

quencing cloning strategy that identified 173 regulatory elements associated with ER α that were active in transfection assays (25). However, there was a poor correlation between the presence of regulatory elements and the regulation of the nearest gene by real-time PCR (25). This finding suggested that the regulatory elements regulated distant genes rather than the closest gene (26). In this study, we combined expression data with ChIP-Seq analysis to identify functional ER β binding sites in target genes.

EXPERIMENTAL PROCEDURES

Cell Lines and Cell Culture—Tetracycline-inducible U2OS-ER α and U2OS-ER β cells were maintained as described previously (20). The cells were maintained continuously in phenol red-free medium with fetal bovine serum stripped of estrogens.

Microarrays and Data Analysis—Total cellular RNA was isolated utilizing the Aurum RNA isolation kit, (Bio-Rad, Hercules, CA), per the manufacturer's directions. RNA isolates were first quantified by standard spectrophotometry and then qualitatively evaluated by capillary electrophoresis employing the Bio-Rad Experion system per the manufacturer's instructions. Biotin-labeled cRNA samples were prepared with 750 ng of total RNA template. Following synthesis and purification, the biotin-labeled samples were evaluated by both 260/280 absorbance spectrophotometry and capillary electrophoresis. The final labeled cRNA samples were hybridized overnight against 48,000 transcripts of humanWG-6 BeadChip arrays (Illumina, San Diego, CA). The Illumina microarrays were processed at the University of California, San Francisco Genomics Core. All treatments were done in triplicate, and the same batch of microarrays were used for all treatments. The Illumina expression arrays were preprocessed using lumi package (27). The differential expression analysis was performed using the Limma package (28). These packages are all available in R/BioConductor. Probes were selected for further analysis if the fold change was >2 and if the multiple testing adjusted p value using Benjamini and Hochberg procedure (BH-adjusted p value) was <0.05 (29). The heat maps of log intensities of genes across different experiments were produced using Cluster and TreeView software (30). Cluster software was used to perform the hierarchical clustering based on Pearson correlation coefficients to find clusters of genes with similar expression patterns. TreeView was then used to visualize the clusters and produce the figures. All microarray data are available on the Gene Expression Omnibus (accession number GSE21790).

RNA Extraction and Reverse Transcription-PCR—Total RNA was extracted and isolated with the Aurum RNA isolation kit (Bio-Rad) per the manufacturer's directions. Reverse transcription reactions were performed using 1 μ g of total RNA as described previously (31). Real-time PCR was performed with the Bio-Rad iCycler using iQ SYBR Green Supermix (Bio-Rad). The sequences of the primers used are shown in [supplemental Table 1](#).

ChIP-Seq—Amplified ChIP DNA samples were prepared utilizing the ChIP-Seq DNA Sample prep kit per the manufacturer's protocol (Illumina) with the following modifications. Following gel purification and clean up of the adapter-ligated ChIP

DNAs, PCR amplification was performed as described for 20 cycles. Final amplified ChIP DNA libraries were analyzed using the Experion capillary electrophoresis system and 1K DNA chips (Bio-Rad). Cluster preparation and subsequent single-read sequencing was performed at Vincent J. Coates' Genomics Sequencing Laboratory (University of California, Berkeley). MACS peak caller was used to identify ER β binding sites for ChIP-seq data (32). Peaks with p values $<10^{-20}$ were selected for further analysis. All ChIP-seq data have been deposited in the Gene Expression Omnibus (accession number GSE21790).

Motif Analysis—CisGenome software (33) was used to scan the peak sequences (400 bp around the peak center) with Transfac weight matrices (34). A segment was claimed as a predicted motif if its log 10 of likelihood ratio score was at least 3.6. To identify known and novel factors enriched near class I and II genes, the best 138 doxycycline peaks within 5 kb of class I genes and 132 doxycycline + E2 peaks within 5 kb of class II genes were investigated for motif enrichment. Four hundred bases centered on the peak centers were compared with the background sequences consisting of matched genomic controls, which contained sequences of the same number and length as peak sequences and were randomly chosen to match the physical distribution of the peak regions (33). Only motifs with a frequency of $>8\%$ among the investigated peaks and >1.9 -fold relative enrichment compared with the background sequences were considered as enriched.

Chromatin Immunoprecipitation (ChIP)—Cells were treated as indicated in the figure legends and then were cross-linked, collected, and lysed as described previously (35). Immunoprecipitations were performed overnight at 4 $^{\circ}$ C with anti-ER β (6A12 14C8, and 7B10; GeneTex, San Antonio, TX) or anti-NCOA2 (GRIP1; Abcam, Cambridge, MA). PCR was done with primers shown in [supplemental Table 1](#). Experiments were done in triplicate, and the mean \pm S.E. was calculated, and statistical analysis was performed using the Prism curve-fitting program (Graph Pad Software, version 3.03). Results are representative of data collected from at least three experiments.

RESULTS

ER β Regulates Three Classes of Target Genes—Our main objective was to identify target genes for unliganded and liganded ER β and binding sites for ER β in the regulated genes by ChIP-Seq. We used U2OS cell lines that were stably transfected with a doxycycline-inducible ER β (20). This feature allowed us to measure the effects of unliganded ER β in cells that were treated only with doxycycline and liganded ER β when the cells were treated with both doxycycline and E $_2$. For comparison, we also used U2OS-ER α cells for the microarray analysis. We previously reported that the U2OS-ER α and U2OS-ER β cells express comparable levels of receptors after induction with doxycycline (20, 36). The cells were maintained in the absence or presence of doxycycline for 18 h to induce the expression of ERs. Following treatment with E $_2$, total RNA was isolated, and then microarrays were performed. The heat maps show that a significant change in the gene expression pattern in the U2OS-ER α cells occurred only with the addition of E $_2$ (Fig. 1A). Doxycycline produced a small up-regulation of only one gene and down-regulation of three genes (Table 1). The addition of E $_2$ to




FIGURE 1. Heat map representation of the genes regulated by unliganded and liganded ER α or ER β . U2OS-ER α (A) or U2OS-ER β (B) cells were treated in the absence (– Doxy) or presence (+ Doxy) of doxycycline for 18 h with or without 10 nM E $_2$. For each gene (row), the average log intensities are colored *yellow*, relatively higher expression are colored with *reds* of increasing intensity, and relatively lower expression are colored with *blues* of increasing intensity. Each treatment represents the average signal of triplicate samples.

TABLE 1

Number of genes regulated in the U2OS-ER α and U2OS-ER β cells

The cells were untreated (–Doxy), or treated with doxycycline alone (+Doxy), or doxycycline and estradiol (+Doxy + E $_2$) for 18 h. The genes listed were significantly regulated by at least 2.0-fold (BH-adjusted *p* value ≤ 0.05).

	No. of genes regulated		
	Up-regulated	Down-regulated	Total
U2OS-ERα cells			
+Doxy versus –Doxy	1	3	4
+Doxy + E $_2$ versus –Doxy	519	192	711
+Doxy + E $_2$ versus +Doxy	518	157	675
U2OS-ERβ cells			
+Doxy versus –Doxy	401	135	536
+Doxy + E $_2$ versus –Doxy	894	354	1248
+Doxy + E $_2$ versus +Doxy	308	33	341

doxycycline-treated U2OS-ER α cells resulted in the activation of 518 genes and repression of 157 genes (Table 1), demonstrating that ER α is functional in these cells. These data indicate that ER α requires the ligand to regulate gene transcription in U2OS cells. In contrast, doxycycline-induced expression of ER β in U2OS cells produced a dramatic change in the gene expression pattern (Fig. 1B). In the absence of ligand, ER β expression was followed by the up-regulation of 401 genes and down-regulation of 135 genes by at least 2-fold (Table 1).

The addition of E $_2$ to U2OS-ER β cells treated with doxycycline led to an up-regulation of 308 genes and down-regulation of 33 genes (Table 1). Interestingly, we could distinguish between three distinct classes of regulated genes in the U2OS-ER β cells (Table 2). There were 453 class I genes regulated by unliganded ER β . Class II genes were 258 genes not regulated by unliganded ER β but regulated by E $_2$ -bound ER β . Class III genes were 83 genes regulated by unliganded ER β and potentiated by the addition of E $_2$ (Table 2). The three classes of regulated genes in the U2OS-ER β cells are listed in [supplemental Table 2](#). To

TABLE 2

Three classes of genes are regulated in U2OS-ER β cells

Following doxycycline treatment, ER β is expressed in the cells and regulates the expression of the class I genes in the absence of ligand. The addition of E $_2$ induces the expression of the class II genes and potentiates the expression of the class III genes.

	No. of genes regulated
Class I (regulated by unliganded ER β only)	453
Class II (regulated by E $_2$ only)	258
Class III (regulated by unliganded ER β and E $_2$)	83




FIGURE 2. ER β regulates three classes of target genes in U2OS cells. U2OS-ER β cells were not treated or treated for 18 h with 10 nM E $_2$ in the absence or presence of doxycycline. Following treatments, mRNA levels for *MSMB* (A), *TMOD1* (B), *CECR6* (C), *DHRS9* (D), *CST5* (E), or *HAVCR2* (F) were measured by real-time PCR (*n* = 6). Unliganded ER β induces expression of class I genes (A and B), whereas class II genes are regulated following E $_2$ treatment (C and D). Class III genes are induced by unliganded ER β and potentiated by E $_2$ treatment (E and F). Each data point is the average of triplicate determinations \pm SEM. Asterisk denotes *p* value ≤ 0.05 .

verify the results of the microarray, we selected two genes in each class and studied their regulation by real-time PCR. Similar to the microarray data, doxycycline produced a strong activation of the class I genes, *MSMB* and *TMOD1* in the absence of ligand (Fig. 2, A and B, respectively). The *CECR6* and *DHRS9* class II genes were not activated by doxycycline, but were stimulated by E $_2$ (Fig. 2, C and D, respectively). The class III genes, *CST5* and *HAVCR2* were activated by unliganded ER β and markedly potentiated with the addition of E $_2$ (Fig. 2, E and F, respectively). The RT-PCR data confirm that there are three classes of genes regulated by ER β but show that the different classes are relative, rather than a definite distinction.

Identification of ER β Binding Sites by ChIP-Seq—To investigate the mechanism whereby ER β can regulate three classes of genes, we performed ChIP-Seq to identify ER β binding sites and transcription factor motifs in each class of genes. After the addition of doxycycline, U2OS-ER β cells were treated in the absence or presence of E $_2$ and then DNA was immunoprecipitated with antibodies to ER β . The DNA fragments were sequenced and mapped to the human genome (HG18 assembly) using Eland. Peaks with *p* values $< 10^{-20}$ were selected for further analysis. Using this cut-off, there were 5,768 binding sites predicted for unliganded ER β and 11,975 binding sites predicted for liganded ER β .

The Majority of Genome-wide ER β Binding Sites Are Present within 50 kb of Genes—When ER β was expressed without a ligand, the majority (76%) of ER β binding sites were located

Genome-wide ER β Binding Sites

within 50 kb of a gene. About 25% of these sites occurred within a gene, 13% were in proximal promoter region of genes, 2% at the 3' end of a gene, 36% elsewhere in a more distal region (5–50

TABLE 3

Genome-wide distribution of ER β binding sites

ER β -expressing U2OS cells were treated without (unliganded) and with (liganded) 10 nM E₂ for 1 h. Peak regions were associated with the HG18 RefGene table downloaded from the University of California, Santa Cruz genome browser. Peaks within 5 kb upstream and 2.5 kb downstream of a RefSeq gene TSS were annotated as being in the promoter region. Peaks within 2.5 kb downstream of a TSS and 2.5 kb upstream of 3' end of the gene were annotated as intragenic. Peaks within 2.5 kb upstream of 3' end and 5 kb downstream of 3' end were annotated as the 3' end. Peaks within 50 kb of a gene but excluded from the above three categories were annotated as within 50 kb. Peaks falling outside of 50 kb window of any gene were labeled as others and considered as peaks involved in long range interactions.

Distribution	Unliganded ER β	Liganded ER β
	%	%
Promoter	13	12
Intragenic	25	25
3' end	2	2
Within 50 kb	36	38
Others	24	23

kb), and the remaining 24% were >50 kb from a gene (Table 3). A similar distribution of ER β binding sites were observed when E₂ was present (Table 3). The genome-wide distribution of ER β binding sites is significantly different from that expected under a random distribution, with more enrichment within 50 kb of genes, specifically, in distal regions (5–50 kb) and proximal promoter regions of genes (p value $< 2 \times 10^{-16}$ based on a chi-square test).

We then focused on the distribution of ER β binding sites within 5 kb of genes because it is likely that many of these sites will be involved in regulating the activity of genes. For class I genes, when ER β is expressed without its ligand, 26% of ER β binding sites were located in promoters, 68% in intragenic regions, and 6% in 3' end regions (Fig. 3A). For class II genes, with the addition of E₂ more ER β binding sites (38%) were found at promoters, whereas 53% were present in intragenic regions and 9% in 3' end regions (Fig. 3B). These findings demonstrated that there is an enrichment of ER β binding sites in the promoter and 3' end regions of class II genes, (47%) compared

with class I genes (32%) with a p value of 0.004 using a binomial test.

ER β Binding Sites Are Enriched in Target Genes—To examine whether the ER β binding sites are likely to be functional, we focused on the ER β binding sites that were in close proximity (5 kb) to the transcriptional start site of the three classes of regulated genes. About 11% of all genes had binding sites within 5 kb in unliganded samples, whereas 20% had sites within 5 kb in E₂-treated samples (Table 4). When the analysis was restricted to regulated genes in the three classes, we found that 43% of the class I genes had unliganded ER β sites, 76% of the class II genes had liganded ER β binding sites, and 60 and 82% of class III genes had unliganded and liganded ER β binding sites within 5 kb, respectively. These percentages are significantly higher than the corresponding percentages observed for all genes (p values $< 2.2 \times 10^{-16}$ based on a binomial test).

The average number of sites within 5 kb in these three classes of genes was also much higher compared with unregulated genes. The enrichment of ER β binding sites near class II and




FIGURE 3. Bioinformatic analysis of ER β binding sites. A and B, pie diagram showing distribution of ER β binding sites within 5 kb of class I and II genes. The peaks within 5 kb of class I and II gene distribution were analyzed with U2OS-ER β cells (A) treated with doxycycline and ER β expressing U2OS cells treated with 10 nM E₂ (B) for 1 h. Peaks within 5 kb upstream and 2.5 kb downstream of the transcriptional start site were annotated as the "Promoter" region. Peaks within 2.5 kb downstream of a transcriptional start site and 2.5 kb upstream of the 3' end of the gene were annotated as "Intragenic." Peaks within 2.5 kb upstream of 3' end and 5 kb downstream of 3' end were annotated as "3' end." C, sequence logo for AP1 in doxycycline sample. D, sequence logo for ERE in doxycycline + E₂ samples. E, density of distance of AP1 motifs to the center of the binding region in doxycycline sample. F, density of distance of ERE motifs to the center of the binding region in doxycycline + E₂ samples.

TABLE 4**Proportion of genes with ER β binding site peaks within 5 kb region**ER β -expressing U2OS cells were treated with doxycycline alone (Doxy) for 18 h, followed by vehicle or 10 nM E₂ (Doxy + E₂) treatment for 1 h.

Category	Proportion of genes having peaks within 5 kb
	%
Class I (Doxy)	42.9
Class II (Doxy + E ₂)	75.5
Class III	
Doxy	60.3
Doxy + E ₂	82.2
All genes	
Doxy	11.3
Doxy + E ₂	20.2

class III genes in E₂-treated samples indicates that E₂ causes more ER β recruitment to regulated genes.

AP1 Sites Are Enriched in Class I Genes Relative to Class II Genes—To investigate the mechanism whereby ER β regulates different classes of genes, we next searched for the enrichment of known motifs involved in ER regulation that are adjacent to ER β binding sites in the three classes of genes. In addition to the classical ERE, other motifs have been shown to be important for ER-mediated transcription, including AP1, SP1, FOXA1, OCT1, NF κ B1, and PAX2 (6, 37–41). This suggests that differences in adjacent transcription factor motifs in the three classes of genes might account for different pattern of gene regulation. CisGenome software (33) and Transfac (34) weight matrices were used to scan a 400-bp sequence around the peak center for ER β binding sites. Of the known factors, we found that AP1 (Fig. 3C), ERE (Fig. 3D), SP1, NF κ B1, and PAX3 were enriched in the regulated genes compared with the background sequences but not FOXA1, OCT1, and CEBP. In class I genes, only AP1 was enriched by >3-fold, whereas ERE, NF κ B1, and SP1 sites were enriched in class II genes (Table 5A). We examined the location of the AP1 (Fig. 3E) and ERE (Fig. 3F) motifs in relation to the peak center and found that they were centered within the binding regions. In addition to known factors, we searched for potential novel factors that might be important for ER β regulation of genes. MYOD, ETS1, and AP4 were enriched in class I genes (Table 5B), whereas ZEB1, CMAF, HES1, E2F, SREBP1, MYC, TF2P2, AP2, and GTF2I were enriched in class II genes (Table 5C).

Unliganded ER β Binds to All Three Classes of Genes—Our data indicate that the transcription factor motifs that are adjacent to ER β binding sites are different in class I genes compared with class II genes, which could account for some differences in genes regulated by ER β . Another possibility is that unliganded or liganded ER β binds to different genes in three classes of genes. To explore this possibility, we examined the binding of ER β to two members of class I (*MSMB* and *TMOD1*), class II (*CECR6* and *DHRS9*) and class III (*CST5* and *HAVCR2*) genes. We selected PCR primers that spanned the ER β binding peaks from the ChIP-seq data (Fig. 4, A–F). U2OS-ER β cells were treated with doxycycline to induce ER β and then exposed to E₂ for 1 h before ChIP was done. One h was the time of maximal ER β binding (data not shown). For all three classes of genes, ER β bound to the genes in the absence of ligand (Fig. 5, A–F), demonstrating that unliganded ER β is recruited similarly to each class of target genes. The addition of the E₂ did not

TABLE 5**Percentages of known or novel factors enriched near class I and II genes**

Percentages of known ER interacting motifs, unknown motifs enriched in doxycycline peaks near class I genes and motifs enriched in doxycycline + E₂ peaks near class II genes. Only motifs with a frequency of >8% among the investigated peaks and with >1.9-fold relative enrichment compared with the background sequences (matched genomic controls) were considered as enriched. A shows the percentages of known ER-interacting motifs in class I doxycycline peaks and class II doxycycline + E₂ peaks and the ratios of corresponding percentages of enriched motifs. + indicates the enrichment, and – indicates the depletion. B shows the percentages of unknown motifs enriched in class I doxycycline peaks and the ratios of corresponding percentages. Motifs are ranked according to their relative abundance under class I, as compared to class II peaks. C shows the percentages of unknown motifs enriched in class II doxycycline + E₂ peaks and the ratios of corresponding percentages. Motifs are ranked according to their relative abundance under class II, as compared with class I peaks.

A Known factors under all peaks				
Motif	Class I (Doxy)	Class II (Doxy+E2)	Class II / Class I	
NFKB1	- 2	+ 8	3.8	
AP1	+ 25	- 7	0.3	
half ERE	+ 15	+ 25	1.6	
SP1	+ 12	+ 19	1.6	
ERE	+ 23	+ 33	1.4	
PAX3	+ 11	+ 11	1	
FOXA1	- 3	- 3		
OCT1	- 2	- 0		
CEBP	- 4	- 4		

B Novel enriched factors under class I peaks			
Motif	Class I (Doxy)	Class II (Doxy+E2)	Class II / Class I
MYOD	8	4	0.5
ETS1	8	5	0.7
AP4	9	7	0.8

C Novel enriched factors under class II peaks			
Motif	Class II (Doxy+E2)	Class I (Doxy)	Class II / Class I
ZEB1	9	2	4.1
CMAF	10	4	2.7
HES1	12	6	2.1
E2F	11	5	2.1
SREBP1	8	4	1.9
MYC	13	7	1.8
TF2P2	8	5	1.6
AP2	14	9	1.5
GTF2I	10	7	1.4

significantly alter the binding of ER β to the three gene classes. These data suggest that ER β binding is necessary for all three classes of genes but is not sufficient to induce class II gene expression.

NCOA2 Is Differentially Recruited to Some of the ER β Target Genes—Our results show that the differential regulation of gene expression by unliganded and liganded ER β is not due to the selective binding of ER β to the different classes of target genes. Another possible explanation is that unliganded ER β differentially recruits coactivators to the three classes of genes. To investigate this possibility, we performed ChIP for NCOA2, the major coactivator recruited to target genes in U2OS cells (25). NCOA2 recruitment to target genes was maximal following 2 h of treatment with E₂ (25). In the presence of unliganded ER β , NCOA2 was recruited to the class I genes *MSMB* and *TMOD1* (Fig. 6, A and B) but not the class II genes *CECR6* and *DHRS9* (Fig. 6, C and D). In contrast, the addition of E₂




FIGURE 4. ER β binding sites in class I, II, and III genes. U2OS-ER β cells were treated with or without doxycycline (Doxy) for 18 h and followed by vehicle or 10 nM E $_2$ (doxycycline + E $_2$) treatment for 1 h. ER β binding sites near class I genes *MSMB* (A) and *TMOD1* (B), class II genes *CECR6* (C) and *DHRS9* (D), and class III genes *CST5* (E) and *HAVCR2* (F) were plotted as the density of 26-bp tags mapping to the region. Figures were produced using the University of California, Santa Cruz genome browser.




FIGURE 5. Recruitment of ER β to class I, II, and III genes in U2OS cells. U2OS-ER β cells were treated with or without doxycycline for 18 h, followed by vehicle or 10 nM E $_2$ treatment for 1 h. Following treatments, ChIP for ER β was performed. Recruitment of ER β to the class I genes, *MSMB* (A) and *TMOD1* (B), class II genes *CECR6* (C) and *DHRS9* (D), or class III genes *CST5* (E) and *HAVCR2* (F) were measured by real-time PCR ($n = 3$). Each data point is the average of triplicate determinations \pm SEM. Asterisk denotes p value ≤ 0.05 .

recruited NCOA2 to the *CERC6* and *DHRS9* genes. Both unliganded and liganded ER β recruited NCOA2 to the class III genes *CST5* and *HAVCR2* (Fig. 6, E and F). These results demonstrated that NCOA2 is differentially recruited to these genes by unliganded and liganded ER β .

DISCUSSION

ER β has potent antiproliferative (15, 16) and anti-inflammatory properties (42, 43), which indicate that ER β selective agonists could be useful therapeutic and chemopreventative agents. To exploit these properties, it is crucial to understand how ER β regulates genes and why it has different properties than ER α , which is associated with cell proliferation and tumor formation. Our microarray data show that ER α and ER β regulate different genes. Furthermore, we found that unliganded ER β but not unliganded ER α regulates numerous genes in U2OS cells. The different effects by unliganded ERs were not due to differences in the levels of ER α and ER β because we previously reported that the U2OS cell lines express comparable levels of receptors after induction with doxycycline (20, 36). These findings indicate that unliganded action is a unique property of ER β in U2OS cells.




FIGURE 6. Recruitment of NCOA2 to class I, II, and III genes in U2OS cells. U2OS-ER β cells were treated with or without doxycycline for 18 h, followed by vehicle or 10 nM E₂ treatment for 2 h. Following treatments, ChIP for NCOA2 was performed. Recruitment of NCOA2 to the class I genes, *MSMB* (A) and *TMOD1* (B), class II genes *CECR6* (C) and *DHR9* (D), or class III genes *CST5* (E) and *HAVCR2* (F) were measured by real-time PCR ($n = 3$). Each data point is the average of triplicate determinations \pm SEM. Asterisk denotes p value ≤ 0.05 .

Whereas ER α only regulated a single class of genes that was dependent on the presence of ligand, microarray analysis revealed that there are three distinct classes of genes regulated by ER β . Class I genes are regulated primarily by unliganded ER β , class II genes are regulated only by liganded ER β , and class III genes are regulated by unliganded ER β and potentiated with the addition of E₂. Real-time PCR of multiple genes verified the microarray data, demonstrating the existence of the three classes of regulated genes. To begin to understand how ER β regulates the different classes of genes, we performed ChIP-seq to identify genome-wide ER β binding sites. We found that there were >5,000 ER β binding sites for unliganded ER β and >11,000 sites for liganded ER β . This number of binding sites is consistent with the number of ER α binding sites identified with genomic tiling arrays (6) and ChIP-seq (24). The location of the binding sites showed that most of the unliganded and liganded ER β binding sites are present within genes. About 13% of the ER β binding sites were found in the proximal promoters, which suggest that these sites are involved in gene regulation.

Our findings raise several important questions regarding the action of ERs. For example, how do ER α and ER β regulate different genes? The most likely explanation is that ER α and ER β bind to different regulatory elements on target genes. The ER α binding sites on chromosomes 1 and 6 were previously reported using tiling arrays in U2OS cells expressing ER α (23). We compared the ER β binding sites on these two chromosomes and found that only ~34% of the ER β binding sites overlapped with ER α binding sites. The ER α binding sites have also been characterized in MCF-7 breast cancer cells that express ER α . It has been shown that there is very little overlap of ER α binding sites in U2OS cells compared with MCF-7 cells, because of different ER α cisomes in these cells (23). Our comparison of the data reveals that the ER β binding sites in U2OS cells overlapped with 11% (23) or 27% (24) ER α binding sites in MCF-7 cells. One possible explanation for the little overlap of ER α and ER β binding sites is that ERs interact with different cis-regulatory elements. Multiple transcription factor motifs are enriched in the cisome of ER α binding sites including, FOXA1, AP1, GATA,

OCT1, and CEBP (6, 39, 44). Of these factors, only AP1 was enriched at ER β binding sites. Taken together, our results indicate that the majority of the ER β binding sites are distinct from ER α binding sites in both U2OS and MCF-7 cells, probably because the transcription factors adjacent ER α and ER β binding sites are different.

Another important question raised by our findings is: how does ER β regulate three different classes of genes? We investigated three possibilities. First, we examined if transcription factors motifs adjacent to ER β bindings were different in class I and II genes. We found that AP1, MYOD, AP4, and ETS1 binding sites were enriched in class I genes compared with class II genes. Other motifs were enriched in class II genes, including elements known to mediate ER responses, such as ERE, NF κ B1, and SP1. Class II genes were also enriched in sites not known to be involved in ER regulation. These include ZEB1, CMAF, HES1, E2F, SREBP1, MYC, TFCP2, AP2, and GTF2I. Our findings indicate that some differences in gene regulation by ER β are likely due to its interaction with different transcription factors that are adjacent to the ER β binding site in the three classes of genes.

Another potential mechanism that we investigated is that the unliganded and liganded forms of ER β bind differentially to the three classes of genes. However, this does not occur because we found that ER β bound similarly to members of the three classes of genes in the absence or presence of ligand. Based on this finding, it appears that the unliganded ER β can bind to all three classes of genes but can only regulate class II and III when the ligand is present. Another possible mechanism for the differences in the regulation of genes by ER β is the differential recruitment of coactivators to ER β . We found that the coactivator NCOA2 is recruited by unliganded ER β in two of the class I and two of the class III genes, whereas only the ligand causes recruitment of NCOA2 to two of the class II genes. Our data indicate that in these genes, unliganded ER β is bound to the regulatory elements in all three classes of genes but is activated by the recruitment of NCOA2. When ER β is bound to class I and III genes, it is capable of recruiting NCOA2 in the absence of ligand. In contrast, in the two class II genes, the bound ER β recruits NCOA2 only when it binds the ligand. While these findings suggest that NCOA2 recruitment is important for determining the class of genes regulated, this needs to be confirmed by studying NCOA2 recruitment to a much larger set of genes by tiling arrays or ChIP-seq. It is well established from structural studies that binding of the ligand moves helix 12 in the ligand binding domain into a position that allows the recruitment of coactivators (45, 46). It is likely that when unliganded ER β is bound to some class I and III genes helix 12 is in a position that allows coactivator recruitment even without ligand, whereas in class II genes, the repositioning of helix 12 by the ligand is essential for the binding of coactivators. Because there are numerous co-factors involved regulating ER action (9, 47, 48) it is likely that other cofactors besides NCOA2 are also important for the differences in gene regulation observed with unliganded and liganded ER β .

In summary, we found that ER β has different properties than ER α in that it regulates three distinct classes of genes. Surprisingly, the unliganded form of ER β regulated more genes than

the liganded form. The differential regulation of genes by unliganded and liganded ER β is likely due to differences in the adjacent transcription factors and cofactors that interact with ER β at the three classes of regulated genes. Our findings raise the possibility that drugs that increase the production of the unliganded form of ER β in cells may be valuable therapeutic agents.

Acknowledgment—We thank Jan-Åke Gustafsson for providing plasmids.

REFERENCES

- Riggs, B. L., Khosla, S., and Melton, L. J., 3rd (2002) *Endocr. Rev.* **23**, 279–302
- Mendelsohn, M. E., and Karas, R. H. (1999) *N. Engl. J. Med.* **340**, 1801–1811
- Katzenellenbogen, B. S., Montano, M. M., Ediger, T. R., Sun, J., Ekena, K., Lazennec, G., Martini, P. G., McInerney, E. M., Delage-Mourroux, R., Weis, K., and Katzenellenbogen, J. A. (2000) *Recent Prog. Horm. Res.* **55**, 163–193
- Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., and Gustafsson, J. A. (2007) *Physiol. Rev.* **87**, 905–931
- Levin, E. R. (2005) *Mol. Endocrinol.* **19**, 1951–1959
- Carroll, J. S., Meyer, C. A., Song, J., Li, W., Geistlinger, T. R., Eeckhoute, J., Brodsky, A. S., Keeton, E. K., Fertuck, K. C., Hall, G. F., Wang, Q., Bekiranov, S., Sementchenko, V., Fox, E. A., Silver, P. A., Gingeras, T. R., Liu, X. S., and Brown, M. (2006) *Nat. Genet.* **38**, 1289–1297
- Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., and Brown, M. (2000) *Cell* **103**, 843–852
- Métivier, R., Penot, G., Hübner, M. R., Reid, G., Brand, H., Kos, M., and Gannon, F. (2003) *Cell* **115**, 751–763
- Smith, C. L., and O'Malley, B. W. (2004) *Endocr. Rev.* **25**, 45–71
- Lonard, D. M., Lanz, R. B., and O'Malley, B. W. (2007) *Endocr. Rev.* **28**, 575–587
- Hewitt, S. C., Harrell, J. C., and Korach, K. S. (2005) *Annu. Rev. Physiol.* **67**, 285–308
- Krege, J. H., Hodgin, J. B., Couse, J. F., Enmark, E., Warner, M., Mahler, J. F., Sar, M., Korach, K. S., Gustafsson, J. A., and Smithies, O. (1998) *Proc. Natl. Acad. Sci. U.S.A.* **95**, 15677–15682
- Lubahn, D. B., Moyer, J. S., Golding, T. S., Couse, J. F., Korach, K. S., and Smithies, O. (1993) *Proc. Natl. Acad. Sci. U.S.A.* **90**, 11162–11166
- Shim, G. J., Wang, L., Andersson, S., Nagy, N., Kis, L. L., Zhang, Q., Mäkelä, S., Warner, M., and Gustafsson, J. A. (2003) *Proc. Natl. Acad. Sci. U.S.A.* **100**, 6694–6699
- Paruthiyil, S., Parmar, H., Kerekatte, V., Cunha, G. R., Firestone, G. L., and Leitman, D. C. (2004) *Cancer Res.* **64**, 423–428
- Ström, A., Hartman, J., Foster, J. S., Kietz, S., Wimalasena, J., and Gustafsson, J. A. (2004) *Proc. Natl. Acad. Sci. U.S.A.* **101**, 1566–1571
- Lazennec, G., Bresson, D., Lucas, A., Chauveau, C., and Vignon, F. (2001) *Endocrinology* **142**, 4120–4130
- Hartman, J., Edvardsson, K., Lindberg, K., Zhao, C., Williams, C., Ström, A., and Gustafsson, J. A. (2009) *Cancer Res.* **69**, 6100–6106
- Hartman, J., Lindberg, K., Morani, A., Inzunza, J., Ström, A., and Gustafsson, J. A. (2006) *Cancer Res.* **66**, 11207–11213
- Kian Tee, M., Rogatsky, I., Tzagarakis-Foster, C., Cvoró, A., An, J., Christy, R. J., Yamamoto, K. R., and Leitman, D. C. (2004) *Mol. Biol. Cell* **15**, 1262–1272
- Monroe, D. G., Getz, B. J., Johnsen, S. A., Riggs, B. L., Khosla, S., and Spelsberg, T. C. (2003) *J. Cell. Biochem.* **90**, 315–326
- Carroll, J. S., and Brown, M. (2006) *Mol. Endocrinol.* **20**, 1707–1714
- Krum, S. A., Miranda-Carboni, G. A., Lupien, M., Eeckhoute, J., Carroll, J. S., and Brown, M. (2008) *Mol. Endocrinol.* **22**, 2393–2406
- Welboren, W. J., van Driel, M. A., Janssen-Megens, E. M., van Heeringen, S. J., Sweep, F. C., Span, P. N., and Stunnenberg, H. G. (2009) *EMBO J.* **28**, 1418–1428
- Levy, N., Tatomer, D., Herber, C. B., Zhao, X., Tang, H., Sargeant, T., Ball, L. J., Summers, J., Speed, T. P., and Leitman, D. C. (2008) *Mol. Endocrinol.* **22**, 287–303
- Fullwood, M. J., Liu, M. H., Pan, Y. F., Liu, J., Xu, H., Mohamed, Y. B., Orlov, Y. L., Velkov, S., Ho, A., Mei, P. H., Chew, E. G., Huang, P. Y., Welboren, W. J., Han, Y., Ooi, H. S., Ariyaratne, P. N., Vega, V. B., Luo, Y., Tan, P. Y., Choy, P. Y., Wansa, K. D., Zhao, B., Lim, K. S., Leow, S. C., Yow, J. S., Joseph, R., Li, H., Desai, K. V., Thomsen, J. S., Lee, Y. K., Karuturi, R. K., Herve, T., Bourque, G., Stunnenberg, H. G., Ruan, X., Cacheux-Rataboul, V., Sung, W. K., Liu, E. T., Wei, C. L., Cheung, E., and Ruan, Y. (2009) *Nature* **462**, 58–64
- Du, P., Kibbe, W. A., and Lin, S. M. (2008) *Bioinformatics* **24**, 1547–1548
- Smyth, G. K. (2004) *Stat. Appl. Genet. Mol. Biol.* **3**, Article3
- Dudoit, S., Shaffer, J. P., and Boldrick, J. C. (2003) *Statistical Science* **18**, 71–103
- Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. (1998) *Proc. Natl. Acad. Sci. U.S.A.* **95**, 14863–14868
- Vivar, O. I., Lin, C. L., Firestone, G. L., and Bjeldanes, L. F. (2009) *Biochem. Pharmacol.* **78**, 469–476
- Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nussbaum, C., Myers, R. M., Brown, M., Li, W., and Liu, X. S. (2008) *Genome Biol.* **9**, R137
- Ji, H., Jiang, H., Ma, W., Johnson, D. S., Myers, R. M., and Wong, W. H. (2008) *Nat. Biotechnol.* **26**, 1293–1300
- Wingender, E., Chen, X., Hehl, R., Karas, H., Liebich, I., Matys, V., Meinhardt, T., Prüss, M., Reuter, L., and Schacherer, F. (2000) *Nucleic Acids Res.* **28**, 316–319
- Vivar, O. I., Saunier, E. F., Leitman, D. C., Firestone, G. L., and Bjeldanes, L. F. (2010) *Endocrinology* **151**, 1662–1667
- Levy, N., Paruthiyil, S., Zhao, X., Vivar, O. I., Saunier, E. F., Griffin, C., Tagliaferri, M., Cohen, I., Speed, T. P., and Leitman, D. C. (2010) *Mol. Cell. Endocrinol.* **315**, 201–207
- Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., and Webb, P. (2000) *J. Steroid Biochem. Mol. Biol.* **74**, 311–317
- Saville, B., Wormke, M., Wang, F., Nguyen, T., Enmark, E., Kuiper, G., Gustafsson, J. A., and Safe, S. (2000) *J. Biol. Chem.* **275**, 5379–5387
- Carroll, J. S., Liu, X. S., Brodsky, A. S., Li, W., Meyer, C. A., Szary, A. J., Eeckhoute, J., Shao, W., Hestermann, E. V., Geistlinger, T. R., Fox, E. A., Silver, P. A., and Brown, M. (2005) *Cell* **122**, 33–43
- Hurtado, A., Holmes, K. A., Geistlinger, T. R., Hutcheson, I. R., Nicholson, R. I., Brown, M., Jiang, J., Howat, W. J., Ali, S., and Carroll, J. S. (2008) *Nature* **456**, 663–666
- Cvoró, A., Tzagarakis-Foster, C., Tatomer, D., Paruthiyil, S., Fox, M. S., and Leitman, D. C. (2006) *Mol. Cell* **21**, 555–564
- Cvoró, A., Paruthiyil, S., Jones, J. O., Tzagarakis-Foster, C., Clegg, N. J., Tatomer, D., Medina, R. T., Tagliaferri, M., Schaufele, F., Scanlan, T. S., Diamond, M. I., Cohen, I., and Leitman, D. C. (2007) *Endocrinology* **148**, 538–547
- Cvoró, A., Tatomer, D., Tee, M. K., Zogovic, T., Harris, H. A., and Leitman, D. C. (2008) *J. Immunol.* **180**, 630–636
- Lupien, M., and Brown, M. (2009) *Endocr.-Relat. Cancer* **16**, 381–389
- Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and Greene, G. L. (1998) *Cell* **95**, 927–937
- Nettles, K. W., and Greene, G. L. (2005) *Annu. Rev. Physiol.* **67**, 309–333
- Westin, S., Rosenfeld, M. G., and Glass, C. K. (2000) *Adv. Pharmacol.* **47**, 89–112
- Green, K. A., and Carroll, J. S. (2007) *Nature Rev. Cancer* **7**, 713–722